Relmada Therapeutics (NASDAQ:RLMD) Releases Earnings Results

Relmada Therapeutics (NASDAQ:RLMD) issued its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.13), Zacks reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV‑01 phase II 12‑month data reported a 76% 12‑month complete response rate overall and 80% in BCG‑unresponsive patients (CR anytime 95% overall, 94% BCG‑unresponsive) with a favorable safety profile (no progression to muscle‑invasive disease, no cystectomies, no grade ≥3 treatment‑related AEs).
• Relmada secured FDA alignment on a two‑pathway registrational strategy and plans to initiate the phase III RESCUE program mid‑2026—an adjuvant randomized trial in intermediate‑risk NMIBC (vs observation) and a single‑arm BCG‑unresponsive trial, with initial 3‑month readouts expected by end‑2026.
• The company completed a $160M private financing and reported $93M cash at year‑end 2025, which management states provides runway through 2029 and to complete the NDV‑01 phase III program.
• Q4 2025 results showed a net loss of $19.9M ($0.27/sh) and higher operating cash burn (net cash used in operations $14.6M in Q4) with increased G&A expenses, reflecting continued development‑stage losses.
• Sepranolone (a GABA‑modulating steroid antagonist) is advancing toward a mid‑2026 proof‑of‑concept trial in Prader‑Willi, but these are company forward‑looking statements and remain subject to clinical and regulatory risks.

Relmada Therapeutics Trading Up 0.6%

RLMD stock opened at $6.25 on Friday. Relmada Therapeutics has a 12-month low of $0.24 and a 12-month high of $7.51. The business’s 50-day moving average is $4.47 and its 200 day moving average is $3.53. The stock has a market cap of $458.31 million, a price-to-earnings ratio of -3.47 and a beta of 0.72.

Institutional Trading of Relmada Therapeutics

A number of institutional investors have recently made changes to their positions in RLMD. XTX Topco Ltd purchased a new stake in shares of Relmada Therapeutics during the second quarter worth approximately $28,000. Goldman Sachs Group Inc. purchased a new position in Relmada Therapeutics in the 1st quarter valued at $33,000. LMR Partners LLP acquired a new stake in Relmada Therapeutics during the 2nd quarter worth $33,000. Schonfeld Strategic Advisors LLC acquired a new stake in Relmada Therapeutics during the 4th quarter worth $64,000. Finally, Jane Street Group LLC purchased a new stake in shares of Relmada Therapeutics during the second quarter worth $69,000. 45.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RLMD has been the topic of a number of analyst reports. Leerink Partners raised shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a research note on Friday, January 23rd. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Mizuho set a $10.00 target price on shares of Relmada Therapeutics in a research note on Friday, March 13th. Jefferies Financial Group assumed coverage on Relmada Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $9.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Relmada Therapeutics in a research report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.